Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05080647
Other study ID # 995MIGH21
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 20, 2021
Est. completion date June 7, 2022

Study information

Verified date October 2021
Source Neuromotion Labs
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized controlled trial comparing a group in which only child participants play Mightier video games for 8 weeks (Child Play group) to a group in which child and parent participants play Mightier video games for 8 weeks (Child and Parent Play group).


Description:

Mightier is a mobile app-based biofeedback video game platform that facilitates emotion regulation skill-building among children ages 6-14. The technology behind Mightier's mobile app has been validated in two independent sham-controlled randomized controlled trials, where the investigators have seen decreases in clinical symptoms of aggression and disruptive behaviors, as well as lowered family stress without adverse events. The study utilizes a parallel randomized controlled design comparing groups of participant families whose children play Mightier video games without parent play to groups of participant families in which both children and parents play Mightier video games. Self-report measures will be completed by participant children and parents. The study consists of three primary phases: Pre-Study, Active Engagement, and Follow-Up. During the Pre-Study Phase, participants will undergo pre-screening and screening to evaluate interest and eligibility for the study, and participants who consent to participate in the study will complete baseline measures and be randomized into treatment groups. Mightier games will be shipped to participants during or shortly after their Pre-Study call. Participants will be instructed to begin Mightier gameplay as soon as Mightier games arrive at their homes, which will begin the Active Engagement Phase of the study. During the 8-week Active Engagement Phase, participants will be encouraged to play Mightier games in a way that corresponds to their study condition, and they will be offered engagement support in the form of brief weekly check-ins. After completion of the Active phase, participants will have a brief Follow-up phase, consisting of one video call during which child and parent participants will complete self-report follow-up measures.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date June 7, 2022
Est. primary completion date March 19, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 12 Years
Eligibility Inclusion Criteria: - Age 6-12 at the time of screening - Regular access to WiFi (for Mightier gameplay device connection) Exclusion Criteria: - Prior Mightier use - Diagnosed Intellectual Disability (by history) - Planned medication changes during the 8-week study period

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mightier online gameplay
Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a "Mighty Band" heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge.

Locations

Country Name City State
United States Neuromotion Labs Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Neuromotion Labs

Country where clinical trial is conducted

United States, 

References & Publications (5)

Bjureberg J, Ljótsson B, Tull MT, Hedman E, Sahlin H, Lundh LG, Bjärehed J, DiLillo D, Messman-Moore T, Gumpert CH, Gratz KL. Development and Validation of a Brief Version of the Difficulties in Emotion Regulation Scale: The DERS-16. J Psychopathol Behav Assess. 2016 Jun;38(2):284-296. Epub 2015 Sep 14. — View Citation

Nock, M.K., Ferriter, C. & Holmberg, E. Parent Beliefs about Treatment Credibility and Effectiveness: Assessment and Relation to Subsequent Treatment Participation. J Child Fam Stud 16, 27-38 (2007). https://doi.org/10.1007/s10826-006-9064-7

RC Pianta - Unpublished measure, University of Virginia, 1992

Stringaris A, Goodman R, Ferdinando S, Razdan V, Muhrer E, Leibenluft E, Brotman MA. The Affective Reactivity Index: a concise irritability scale for clinical and research settings. J Child Psychol Psychiatry. 2012 Nov;53(11):1109-17. doi: 10.1111/j.1469-7610.2012.02561.x. Epub 2012 May 10. — View Citation

Weisz JR, Vaughn-Coaxum RA, Evans SC, Thomassin K, Hersh J, Ng MY, Lau N, Lee EH, Raftery-Helmer JN, Mair P. Efficient Monitoring of Treatment Response during Youth Psychotherapy: The Behavior and Feelings Survey. J Clin Child Adolesc Psychol. 2020 Nov-Dec;49(6):737-751. doi: 10.1080/15374416.2018.1547973. Epub 2019 Jan 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in child behavior and emotion problems measured on BFS at Week 8 Behavior and Feelings Survey (BFS): The BFS (Weisz et al., 2014) is a 12-item scale measuring child behavior and emotion problems. The child's parent is prompted to read the survey questions to the child and to note the child's responses. The researcher will screen share the BFS form and record child responses in the form. Children will complete the BSF at baseline and Week 8. Items are rated on a scale from 0 (not a problem) to 4 (a very big problem). Three scale scores can be derived: Internalizing Problems (sum of items 1-6), Externalizing Problems (sum of items 7-12), and Total Problems (sum of items 1-12). Baseline and Week 8
Primary Change in child irritability from baseline measured on ARI-P at Week 8 Affective Reactivity Index-Parent Report (ARI-P): The ARI is a 7-item scale that consists of 6 symptom items and 1 impairment item. The scale was designed to determine irritable mood rather than behavioral consequences such as hostility and acts of aggression (Stringaris et al., 2012). The individual items are scored 0,1, 2, and only the first six items are summed to form the total score, with a minimum score of 0 and a maximum score of 18, and higher scores indicating greater severity of irritability symptoms. The seventh item is an impairment item and it is analysed separately, with a minimum score of 0 and a maximum score of 3, and higher scores indicating greater irritability symptom severity. Parent participants will complete the ARI-P at baseline and Week 8. Baseline and Week 8
Primary Parent perception of change in child emotion regulation from baseline measured on GIS at Week 8 Global Improvement Scale (GIS): The GIS is a parent self-report question that asks parents if they have noticed any overall improvements in their child's emotion regulation, with response options ranging from (1) very much improved to (7) very much worse. Minimum score = 1, Maximum score = 7, with higher numbers indicating less improvement, or worsening. The GIS has not been scientifically validated. Parent participants will complete the GIS at Week 8. Baseline and Week 8
Secondary Change in parent emotion regulation from baseline measured on DERS-18 at Week 8 Difficulties in Emotion Regulation Scale, 18-question short form (DERS-18): The DERS-18 (Victor & Klonsky, 2016) is an 18-question measure of the respondent's emotion regulation experiences. For scoring, three responses are reverse-coded then all responses are summed, resulting in an overall score and scores on 6 subscales: Awareness, Clarity, Goals, Impulse, Nonacceptance, and Strategies. Higher scores indicate greater emotion regulation difficulties. Parent participants will complete the DERS-18 at baseline and Week 8. Baseline and Week 8
Secondary Change in parent beliefs about intervention credibility and effectiveness from baseline, measured on the CEQ-P at Week 4 and Week 8 Credibility and Expectancies Questionnaire - Parent Version (CEQ-P): Parent participants will respond to the CEQ-P (Nock et al., 2007), a 6-question assessment of their beliefs about credibility and effectiveness of the intervention, at baseline, Week 4, and Week 8. Items 1, 2, 3, and 5 are scored on a nine-point scale (1 = not a lot / not much; 9 = a lot / very much). Items 4 and 6 are scored on an 11-point scale (e.g., 0-100%), then recoded for scoring to correspond to the 1-9 point scale used for items 1-3 and 5, collapsing the values from 40-60% into one value, 5. Baseline, Week 4, and Week 8
Secondary Change in child-parent relationship from baseline, measured on the CPRS-SF at Week 8 Child-Parent Relationship Scale (CPRS-SF): The CPRS-SF (Pianta, 1992) is a 15-item self-report instrument completed by parents that assesses their perceptions of their relationship with their child. The 15 items are rated on 5-point Likert scales. It is applicable to children ages 3-12. The CPRS-SF is scored in two subscales: an 8-item Conflict subscale (minimum score = 8, maximum score = 40, higher score indicates greater conflict), and a 7-item Closeness subscale (minimum score = 7, maximum score = 35, with greater score indicating greater closeness). Parent participants will complete the CPRS-SF at baseline and Week 8. Baseline and Week 8
See also
  Status Clinical Trial Phase
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05545241 - Awareness of Emotional Feelings and Management of Risky Situations N/A
Completed NCT05543811 - The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology N/A
Completed NCT04558411 - Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students N/A
Completed NCT03124446 - Mindfulness-Based College: Stage 1 N/A
Recruiting NCT04733300 - Online Mindfulness-Based College for Young Adults N/A
Completed NCT06085391 - Testing the Efficacy of the REThink Emotions Platform in a Full-scale SMART Study N/A
Completed NCT05027113 - App-Based Mindfulness Meditation for People of Color Who Experience Race-Related Stress N/A
Completed NCT04536935 - Mobile Mental Health Apps for Suicide Prevention N/A
Completed NCT05607784 - Education Program to Reduce Risky Behavior in Adolescents Ph I
Completed NCT04839861 - Examining the Impacts of Parent-Child Interactive Activities N/A
Completed NCT04942678 - The Impact of Therapy Dogs on Anxiety and Emotional Management in the Pediatric Emergency Department
Completed NCT02661880 - The Role of Music in Palliative Care: A Proposal for a Rural Based Initiative in Music Based Interventions N/A
Recruiting NCT06267521 - The STRENGTHEN Study N/A
Recruiting NCT06054412 - An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers N/A
Recruiting NCT05718427 - Effect of ASI on Sensory, Motor, Cognitive, Behavioral Skills and Social Participation in Children With ADHD N/A
Not yet recruiting NCT05531318 - Emotional Regulation in People With Co-occurring Posttraumatic Stress Disorder and Substance Use Disorder
Recruiting NCT05472545 - Dyadic Neurofeedback for Development of Healthy Emotion Regulation in Youth N/A
Recruiting NCT05022550 - Virtual-reality and Emotion Regulation in Violence-Exposed Youth N/A
Enrolling by invitation NCT05859126 - Maternal Choline Supplementation and Offspring Cognition in Adolescence N/A